{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:04:09Z","timestamp":1781222649769,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.pharma.2026.01.008","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:18:55Z","timestamp":1770164335000},"page":"631-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The pharmacogenetics of Tacrolimus in Algerian kidney recipients\u2019 patients"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4941-3589","authenticated-orcid":false,"given":"Habiba","family":"Fetati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amani","family":"Abderahmene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Boudia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakhdar","family":"Zemour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadjet-Fatima-Zohra","family":"Mekaouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asmaa","family":"Memou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kada","family":"Djoudad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Zerdoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Benslama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"omezzine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houari","family":"Toumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.pharma.2026.01.008_bib0330","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1111\/j.1600-6143.2011.03686.x","article-title":"Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes","volume":"11","author":"Tonelli","year":"2011","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.pharma.2026.01.008_bib0335","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1797.2008.01073.x","article-title":"The cost-effectiveness of increasing kidney transplantation and home-based dialysis","volume":"14","author":"Howard","year":"2009","journal-title":"Nephrol Carlton Vic"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0340","doi-asserted-by":"crossref","first-page":"167","DOI":"10.33549\/physiolres.933332","article-title":"Pathophysiological mechanisms of calcineurin inhibitor-induced nephrotoxicity and arterial hypertension","volume":"66","author":"Ho\u0161kov\u00e1","year":"2017","journal-title":"Physiol Res"},{"issue":"10","key":"10.1016\/j.pharma.2026.01.008_bib0345","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1517\/14740338.2015.1083974","article-title":"The safety of calcineurin inhibitors for kidney-transplant patients","volume":"14","author":"Malvezzi","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"10.1016\/j.pharma.2026.01.008_bib0350","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/ki.2009.377","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary","volume":"77","author":"Kasiske","year":"2010","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.pharma.2026.01.008_bib0355","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/FTD.0b013e3182731809","article-title":"Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation","volume":"34","author":"Ro","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1016\/j.pharma.2026.01.008_bib0360","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10620-012-2412-0","article-title":"Non-adherence and graft failure in adult liver transplant recipients","volume":"58","author":"Lieber","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1016\/j.pharma.2026.01.008_bib0365","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharma.2026.01.008_bib0370","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.pharma.2026.01.008_bib0375","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/TP.0b013e31827eef57","article-title":"CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III)","volume":"95","author":"Yoon","year":"2013","journal-title":"Transplantation"},{"issue":"3 Suppl","key":"10.1016\/j.pharma.2026.01.008_bib0380","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1097\/TP.0b013e3181afe9e7","article-title":"Pharmacogenetics of calcineurin inhibitors in renal transplantation","volume":"88","author":"Coto","year":"2009","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.pharma.2026.01.008_bib0385","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/aps.2012.200","article-title":"Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine through concentrations in Chinese renal transplant recipients","volume":"34","author":"Zhang","year":"2013","journal-title":"Acta Pharmacol Sin"},{"issue":"3","key":"10.1016\/j.pharma.2026.01.008_bib0390","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0395","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/FTD.0b013e31819c3d6d","article-title":"Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients","volume":"31","author":"Press","year":"2009","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pharma.2026.01.008_bib0400","first-page":"275","article-title":"The pharmacogenetics of immune-modulating therapy","volume":"83","author":"Cascorbi","year":"2018","journal-title":"Adv Pharmacol San Diego Calif"},{"issue":"11","key":"10.1016\/j.pharma.2026.01.008_bib0405","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.2217\/pgs.11.129","article-title":"Future of the pharmacogenomics of calcineurin inhibitors in renal transplant patients","volume":"12","author":"Zhu","year":"2011","journal-title":"Pharmacogenomics"},{"issue":"8","key":"10.1016\/j.pharma.2026.01.008_bib0410","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","article-title":"Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients","volume":"76","author":"Thervet","year":"2003","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.pharma.2026.01.008_bib0415","doi-asserted-by":"crossref","first-page":"90","DOI":"10.5500\/wjt.v10.i5.90","article-title":"Pharmacogenetics of immunosuppressant drugs: a new aspect for individualized therapy","volume":"10","author":"Salvadori","year":"2020","journal-title":"World J Transplant"},{"issue":"1","key":"10.1016\/j.pharma.2026.01.008_bib0420","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.pharma.2026.01.008_bib0425","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.pharma.2026.01.008_bib0430","first-page":"3","article-title":"Cytochrome P450 in pharmacogenetics: an update","volume":"83","author":"Tornio","year":"2018","journal-title":"Adv Pharmacol San Diego Calif"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0435","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"10.1016\/j.pharma.2026.01.008_bib0440","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2217\/pgs.15.138","article-title":"Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase","volume":"16","author":"Aouam","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"1","key":"10.1016\/j.pharma.2026.01.008_bib0445","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.5301\/jbm.5000118","article-title":"Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia","volume":"30","author":"Novillo","year":"2015","journal-title":"Int J Biol Markers"},{"issue":"4","key":"10.1016\/j.pharma.2026.01.008_bib0450","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"10.1016\/j.pharma.2026.01.008_bib0455","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/01677063.2016.1155571","article-title":"Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients","volume":"30","author":"Chbili","year":"2016","journal-title":"J Neurogenet"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0460","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1038\/psp.2013.78","article-title":"Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on cyclosporine, everolimus, and tacrolimus pharmacokinetics in renal transplantation","volume":"3","author":"Moes","year":"2014","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"1","key":"10.1016\/j.pharma.2026.01.008_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41397-024-00323-4","article-title":"The pharmacogenetics of tacrolimus in renal transplant patients: association with tremors, new-onset diabetes and other clinical events","volume":"24","author":"Abderahmene","year":"2024","journal-title":"Pharmacogenomics J"},{"issue":"Suppl 1","key":"10.1016\/j.pharma.2026.01.008_bib0470","doi-asserted-by":"crossref","first-page":"77","DOI":"10.6002\/ect.MESOT2021.O35","article-title":"Pediatric versus adult kidney transplant activity in Arab countries","volume":"20","author":"Saeed","year":"2022","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.pharma.2026.01.008_bib0475","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.nephro.2018.07.241","article-title":"Rejet aigu des greffes r\u00e9nales de donneurs vivants apparent\u00e9s HLA identique","volume":"14","author":"Kara","year":"2018","journal-title":"Nephrol Therap"},{"key":"10.1016\/j.pharma.2026.01.008_bib0480","first-page":"232","article-title":"Le don d\u2019organes en Alg\u00e9rie\u00a0: limites et perspectives [Organ donations in Algeria: restrictions and perspectives]","volume":"39","author":"Rekhif","year":"2021","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.pharma.2026.01.008_bib0485","doi-asserted-by":"crossref","first-page":"115000","DOI":"10.1016\/j.taap.2020.115000","article-title":"Effect of CYP3A4*22 and CYP3A4*1B but not CYP3A5*3 polymorphisms on tacrolimus pharmacokinetic model in Tunisian kidney transplant","volume":"396","author":"Hannachi","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0490","first-page":"159","article-title":"CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population","volume":"110","author":"Muller","year":"2020","journal-title":"South Afr Med J Suid-Afr Tydskr Vir Geneeskd"},{"issue":"11","key":"10.1016\/j.pharma.2026.01.008_bib0495","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.3390\/pharmaceutics13111970","article-title":"Effect of the Interrelation between CYP3A5 genotype, concentration\/dose ratio and intrapatient variability of tacrolimus on kidney graft function: Monte Carlo simulation approach","volume":"13","author":"Stefanovi\u0107","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pharma.2026.01.008_bib0500","series-title":"Apport de la pharmacog\u00e9n\u00e9tique dans l\u2019optimisation du traitement aux immunosuppresseurs\u00a0: application au tacrolimus et \u00e0 la ciclosporine","author":"Boudia","year":"2018"},{"issue":"3","key":"10.1016\/j.pharma.2026.01.008_bib0505","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/bcpt.13016","article-title":"CYP3A5*3 and ABCB1 61A>G significantly influence dose-adjusted through blood tacrolimus concentrations in the first three months post-kidney transplantation","volume":"123","author":"Hu","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.pharma.2026.01.008_bib0510","first-page":"23","article-title":"CYP3A5 polymorphisms in renal transplant recipients: influence on tacrolimus treatment","volume":"11","author":"Chen","year":"2018","journal-title":"Pharmacogenomics Pers Med"},{"issue":"4","key":"10.1016\/j.pharma.2026.01.008_bib0515","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41397-019-0144-7","article-title":"CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis","volume":"20","author":"Khan","year":"2020","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.pharma.2026.01.008_bib0520","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3389\/fphar.2020.01142","article-title":"The clinical impact of the C0\/D Ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients","volume":"11","author":"Van Gelder","year":"2020","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.pharma.2026.01.008_bib0525","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/gtmb.2020.0077","article-title":"Tacrolimus starting dose prediction based on genetic polymorphisms and clinical factors in Chinese renal transplant recipients","volume":"24","author":"Wang","year":"2020","journal-title":"Genet Test Mol Biomark"},{"issue":"10","key":"10.1016\/j.pharma.2026.01.008_bib0530","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/jpm11101002","article-title":"Impact of tacrolimus daily dose limitation in renal transplant recipients expressing CYP3A5: a retrospective study","volume":"11","author":"Lenain","year":"2021","journal-title":"J Pers Med"},{"issue":"4","key":"10.1016\/j.pharma.2026.01.008_bib0535","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.transproceed.2022.02.018","article-title":"Renal Cyp3a5-expressing genotype decreases tacrolimus-to-dose ratio in small cohort of renal transplant recipients-preliminary report","volume":"54","author":"Warzyszy\u0144ska","year":"2022","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.pharma.2026.01.008_bib0540","first-page":"156","article-title":"Effects of genetic polymorphism in CYP3A4 and CYP3A5 genes on tacrolimus dose among kidney transplant recipients","volume":"10","author":"Yousef","year":"2016","journal-title":"Iran J Kidney Dis"},{"issue":"10","key":"10.1016\/j.pharma.2026.01.008_bib0545","doi-asserted-by":"crossref","first-page":"e111128","DOI":"10.1371\/journal.pone.0111128","article-title":"The tacrolimus metabolism rate influences renal function after kidney transplantation","volume":"9","author":"Th\u00f6lking","year":"2014","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.pharma.2026.01.008_bib0550","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1159\/000502290","article-title":"Tacrolimus: influence of the post-transplant concentration\/dose ratio on kidney graft function in a two-year follow-up","volume":"44","author":"Nowicka","year":"2019","journal-title":"Kidney Blood Press Res"},{"issue":"6","key":"10.1016\/j.pharma.2026.01.008_bib0555","first-page":"721","article-title":"Optimization of initial tacrolimus dose using pharmacogenetic testing","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharma.2026.01.008_bib0560","doi-asserted-by":"crossref","first-page":"115245","DOI":"10.1016\/j.taap.2020.115245","article-title":"Dosing algorithm for tacrolimus in Tunisian kidney transplant patients: effect of CYP 3A4*1B and CYP3A4*22 polymorphisms","volume":"407","author":"Ben-Fredj","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"issue":"6","key":"10.1016\/j.pharma.2026.01.008_bib0565","doi-asserted-by":"crossref","first-page":"e0127995","DOI":"10.1371\/journal.pone.0127995","article-title":"Effects of the CYP3A4*1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pharma.2026.01.008_bib0570","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41397-020-00179-4","article-title":"Influence of CYP3A polymorphisms on tacrolimus pharmacokinetics in kidney transplant recipients","volume":"21","author":"Hannachi","year":"2021","journal-title":"Pharmacogenomics J"},{"issue":"9","key":"10.1016\/j.pharma.2026.01.008_bib0575","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1016\/j.transproceed.2019.04.090","article-title":"Tacrolimus therapeutic drug monitoring in stable kidney transplantation and individuation of CYP3A5 Genotype","volume":"51","author":"Allegri","year":"2019","journal-title":"Transplant Proc"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0580","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/jpm10020047","article-title":"Failure of achieving tacrolimus target blood concentration might be avoided by a wide genotyping of transplanted patients: evidence from a retrospective study","volume":"10","author":"Pallio","year":"2020","journal-title":"J Pers Med"},{"issue":"6","key":"10.1016\/j.pharma.2026.01.008_bib0585","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, pharmacodynamics and pharmacogenetics of tacrolimus in kidney transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr Drug Metab"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0590","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/clpt.2013.68","article-title":"CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients","volume":"94","author":"Santoro","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.pharma.2026.01.008_bib0595","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00228-014-1656-3","article-title":"The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients","volume":"70","author":"Lunde","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharma.2026.01.008_bib0600","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/FTD.0000000000000142","article-title":"Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus","volume":"37","author":"Bruckmueller","year":"2015","journal-title":"Ther Drug Monit"},{"issue":"8","key":"10.1016\/j.pharma.2026.01.008_bib0605","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2217\/pgs.15.42","article-title":"Multigene predictors of tacrolimus exposure in kidney transplant recipients","volume":"16","author":"Pulk","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0610","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s40268-017-0177-9","article-title":"The pharmacogenetics of tacrolimus in corticosteroid-sparse pediatric and adult kidney transplant recipients","volume":"17","author":"Madsen","year":"2017","journal-title":"Drugs RD"},{"issue":"12","key":"10.1016\/j.pharma.2026.01.008_bib0615","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2217\/pgs.15.78","article-title":"Interactive effects of CYP3A4, CYP3A5, MDR1 and NR1I2 polymorphisms on tracrolimus through concentrations in early post-renal transplant recipients","volume":"16","author":"Li","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharma.2026.01.008_bib0620","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3389\/fgene.2019.00871","article-title":"The impact of CYP3A4*22 on tacrolimus pharmacokinetics and outcome in clinical practice at a single kidney transplant center","volume":"10","author":"Abdel-Kahaar","year":"2019","journal-title":"Front Genet"},{"key":"10.1016\/j.pharma.2026.01.008_bib0625","doi-asserted-by":"crossref","first-page":"912618","DOI":"10.3389\/fphar.2022.912618","article-title":"Why we need to take a closer look at genetic contributions to CYP3A activity","volume":"13","author":"Zhai","year":"2022","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.pharma.2026.01.008_bib0630","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bcp.12345","article-title":"Relationship of CYP3A5 genotype and ABCB1 diplotype to tacrolimus disposition in Brazilian kidney transplant patients","volume":"78","author":"Cusinato","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharma.2026.01.008_bib0635","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2217\/pgs-2017-0187","article-title":"Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients","volume":"19","author":"Oetting","year":"2018","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.pharma.2026.01.008_bib0640","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40262-018-0717-7","article-title":"Pharmacogenetics of membrane transporters of tacrolimus in solid organ transplantation","volume":"58","author":"Tron","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.pharma.2026.01.008_bib0645","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.clinthera.2020.07.016","article-title":"Effect of ABCB1 3435C>T genetic polymorphism on pharmacokinetic variables of tacrolimus in adult renal transplant recipients: a systematic review and meta-analysis","volume":"42","author":"Peng","year":"2020","journal-title":"Clin Ther"},{"issue":"29","key":"10.1016\/j.pharma.2026.01.008_bib0650","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2174\/0113816128259239231009112019","article-title":"The impact of ABCB1 SNPs on tacrolimus pharmacokinetics in liver or kidney transplant recipients: a meta-analysis","volume":"29","author":"Li","year":"2023","journal-title":"Curr Pharm Des"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:21:17Z","timestamp":1781220077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926000088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0003450926000088"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.01.008","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacogenetics of Tacrolimus in Algerian kidney recipients\u2019 patients","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}